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Abstract
Background: Individuals with diabetes are twice as likely to develop peripheral arterial disease
(PAD), the manifestation of extensive atherosclerosis throughout the lower extremities. One
putative determinant of PAD is the 677C>T polymorphism in the gene encoding
methylenetetrahydrofolate reductase (MTHFR), which has previously been found to associate with
various diabetic complications including retinopathy, nephropathy, atherosclerosis and coronary
heart disease. The objective of this study was to investigate a possible role for the MTHFR 677C>T
gene polymorphism with PAD in subjects with type 2 diabetes from an isolated aboriginal Canadian
population.
Methods: The 677C>T MTHFR gene polymorphism was genotyped in 138 subjects of Oji-Cree
descent. Participants were selected from a community-wide survey that included PAD assessment
by ankle-brachial index (ABI) measurement, and also intermittent claudication assessment by the
Rose questionnaire.
Results: MTHFR 677T allele carriers had an increased risk of PAD with an odds ratio of 3.54 (95%
CI 1.01, 12.4), P = 0.049, after adjustment for age, sex, duration of diabetes, hypertension, current
smoking habits, and use of insulin or oral treatment for diabetes. None of these additional co-
variables was significantly associated with PAD. No association was found between MTHFR
genotype and intermittent claudication.
Conclusion: The genetic influence of the MTHFR 677C>T genotype on diabetic PAD is modest,
yet for the Oji-Cree it is a major risk factor in comparison to other traditional risk factors.
Background
Peripheral arterial disease (PAD) of the lower extremities,
due to atherosclerosis occurring at the aortic bifurcation,
femoral and popliteal arteries, commonly manifests as
asymptomatic changes in intermediate phenotypes such
as the ankle-brachial index (ABI). The most common
symptom experienced is the aches and pains of intermit-
tent claudication, and in extreme situations, individuals
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may develop gangrene and require lower-limb amputa-
tions [1]. While most subjects with PAD remain asympto-
matic, all have markedly increased risk of developing
cardiovascular disease, as PAD is fundamentally a sign of
systemic atherosclerosis. Compared with age-matched
controls, patients with intermittent claudication have a
threefold increase in cardiovascular mortality [2,3] and a
low ABI has been shown to be an independent predictor
of both all-cause and cardiovascular mortality [4,5]. The
presence of diabetes is associated with a doubling of PAD
risk [6]; up to 15% of subjects with type 2 diabetes can
have clinically significant PAD [6,7]. Other well-known
risk factors for PAD include hypertension, dyslipidemia,
and smoking [1].
Efforts to determine some of the genetic factors underly-
ing susceptibility to PAD have met limited success [8-14].
Candidate genes include those that have shown associa-
tion with atherosclerosis in other vascular beds. One such
candidate is the gene encoding methylenetetrahydrofolate
reductase (MTHFR), a key enzyme in the alternative path-
way of homocysteine metabolism that remethylates
homocysteine to methionine. Elevated plasma homo-
cysteine has been reported among carriers of the MTHFR
677C>T (Ala222Val; MIM 607093.0003) thermolabile
single nucleotide polymorphism (SNP) [15]. This dys-
functional SNP is associated with reduced enzyme activ-
ity, resulting in a relative deficiency in the remethylation
process [15], leading to elevated plasma homocysteine.
Elevated plasma homocysteine concentration appears to
be significantly associated with PAD [9,16]. Hyperhomo-
cysteinemia may promote vascular disease through
endothelial injury, predisposing the vessel to atheroscle-
rosis [17]. Since the MTHFR 677C>T SNP is an important
determinant of plasma homocysteine concentration, this
polymorphism may represent an important genetic risk
factor in vascular disease.
The MTHFR 677C>T SNP has previously been found to
associate with various diabetic complications, including
retinopathy [18-21], nephropathy [22-25], atherosclero-
sis [26], and coronary heart disease [27]. However, no
studies to date have reported an association specifically
for PAD, as measured, for instance, by the non-invasive
ABI, a tool that has proven its usefulness in predicting
future cardiovascular events [28]. Thus the objective of
this study was to investigate a possible role for the MTHFR
677C>T polymorphism with PAD (ABI) in subjects with
type 2 diabetes.
Research design and methods
Study Sample
Patients in this study were participants in the Sandy Lake
Complications Prevalence and Risk Factor Study, which
was initiated to study the prevalence of, and risk factors
for, complications of type 2 diabetes in aboriginal Cana-
dians [29]. Sandy Lake, Ontario, is a remote Oji-Cree
community, found at the 55th parallel of latitude, in the
subarctic boreal forest of central Canada. For this commu-
nity-based, cross-sectional study, 189 eligible subjects
with type 2 diabetes were enrolled, although the sample
size varied for some variables given time-limited access to
certain diagnostic equipment. Of these, 173 individuals
had available DNA for MTHFR 677C>T genotyping. For
the determination of PAD, 140 subjects participated, with
an overlap of 138 subjects who had both ABI and MTHFR
677C>T genotype determination. Signed informed con-
sent was obtained from all participants. The study was
approved by both the Sandy Lake First Nation Band
Council and the Mount Sinai Hospital Ethics Review
Committee.
Clinical characteristics and biochemical analysis
Measurements of fasting blood analytes, including glu-
cose, lipid and lipoprotein concentrations, and percent
glycoslyated hemoglobin (HbA1c), were performed as
described [30]. Standardized procedures were used to
measure blood pressure, height, weight, and waist circum-
ferences [30]. Information on diabetes duration, diabetes
treatment, and tobacco use, was obtained from inter-
viewer-administered questionnaires [30]. Hypertensive
individuals were defined as those subjects having either
blood pressure exceeding systolic 130 mmHg and/or
diastolic 80 mmHg, and/or receiving antihypertensive
treatment.
Diagnosis of peripheral arterial disease and intermittent 
claudication
The diagnosis of PAD was based on the ABI, which was
measured using a blood pressure cuff and Doppler steth-
oscope. Systolic blood pressure was assessed at 3 sites on
each side (brachial, posterior tibial, and dorsalis pedis
arteries). Left and right ABI measurements were obtained
by selecting the highest leg systolic blood pressure reading
(either the posterior tibial systolic blood pressure or the
dorsalis pedis systolic blood pressure) and dividing it by
the mean brachial systolic blood pressure. The same indi-
vidual performed all measurements. The use of ABI as a
screening test for atherosclerotic disease has been previ-
ously validated [31], and test results have been shown to
have high reproducibility when performed by trained pro-
fessionals [32]. By convention, PAD was defined as an ABI
of less than 0.95; subjects with an ABI greater than 1.40
were considered to have non-compressible vessels [29].
Intermittent claudication was assessed using the Rose
(World Health Organization) questionnaire, with a posi-
tive score indicating the presence of leg pain, using the
provided standard algorithm for diagnosis [33]. Leg pain
was not considered intermittent claudication if it startedCardiovascular Diabetology 2005, 4:17 http://www.cardiab.com/content/4/1/17
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when standing still or sitting, if it did not include the
calves, or if it did not occur when walking up hill or hur-
rying [33].
Genotyping MTHFR 677C>T
An established procedure was used to genotype the
MTHFR 677C>T SNP [15]. Briefly, exon 4 was amplified
using the following primers: 5'-CAA AGG CCA CCC CGA
AGC and 5'-AGG ACG GTG CGG TGA GAG TG. Samples
were amplified for 30 cycles, each of which consisted of
denaturing at 94°C for 30 s, annealing at 58°C for 30 s,
and extension at 72°C for 30 s. After HinfI (New England
Biolabs, Mississauga, Ontario, Canada) digestion of the
resulting 245 bp fragment, the C allele yielded only a sin-
gle 245 bp fragment, and the T allele yielded two frag-
ments with sizes 176 and 69 bp. Electrophoresis in a 2.5%
agarose gel followed by ethidium bromide staining and
ultraviolet illumination allowed detection of the alleles.
Statistical analysis
SAS version 8.2 (SAS Institute, Cary, NC) was used for all
statistical comparisons. Data are presented as means ±
standard deviation (s.d.) or as percentages for categorical
variables. Logarithmic transformations (natural log) were
used if data were not normally distributed. The trans-
formed variables were used for parametric statistical anal-
yses, but the untransformed values are presented in the
tables. For continuous variables, differences between the
groups were tested by the Student's t test; categorical vari-
ables were tested by χ2 analysis or by Fisher's exact test.
PAD was analyzed by multivariate logistic regression, with
MTHFR 677C>T genotype, duration of diabetes, current
smoking habits, blood pressure, antihypertensive treat-
ment, treatment for diabetes (insulin or oral agent), age,
and sex included as independent variables. Deviation of
genotype frequencies from those predicted by Hardy-
Weinberg law was tested by χ2 analysis. All statistical tests
were two-sided and statistical significance was taken at
nominal P < 0.05 for all comparisons.
Results
Characteristics of Oji-Cree type 2 diabetic patients
Study participants (35.5% male) had an average age of
46.7 ± 11.2 years for males and 45.8 ± 11.9 years for
females, and a mean duration of diabetes of 8.27 ± 5.49
years for males and 8.90 ± 6.98 years for females. In com-
parison to males, females had significantly higher BMI
(31.1 ± 5.2 vs 29.0 ± 4.5 kg/m2, P = 0.020), and a lower
frequency of hypertension (55.1% vs 77.6%, P = 0.0088).
Approximately 14% had PAD, with PAD more frequent
on the right side than the left (~12% vs ~8%), and no sig-
nificant difference between the numbers of males and
females affected (14.3% males vs 14.6% females, P=NS
[0.96]). Slightly more than 1 out of 20 subjects had inter-
Table 1: Characteristics of Oji-Cree type 2 diabetic patients according to the presence or absence of PAD (max n = 138)
PAD present PAD absent P
NN
Sex (% male) 20 35.0 118 35.6 NS (0.96)
Age (years) 20 48.0 ± 11.2 118 45.8 ± 11.7 NS (0.44)
BMI (kg/m2) 20 30.4 ± 5.7 117 30.3 ± 4.9 NS (0.98)
Waist circumference (cm) 20 102 ± 13 117 104 ± 9 NS (0.52)
Current smokers (%) 20 65.0 118 47.5 NS (0.15)
Duration of diabetes (years) 20 8.70 ± 4.64 118 8.67 ± 6.76 NS (0.98)
Insulin treatment (%) 16 25.0 98 18.4 NS (0.51)
Intake of antidiabetic drugs (%) 16 31.3 98 58.2 0.045
Taking lipid medication (%) 20 5.0 118 16.1 NS (0.31)
Fasting glucose (mmol/L) 19 10.27 ± 2.79 111 9.96 ± 3.90 NS (0.48)
HbA1c (%) 20 8.30 ± 1.93 116 8.44 ± 2.29 NS (0.92)
Total cholesterol (mmol/L) 19 4.43 ± 0.63 114 4.93 ± 1.06 0.036
Plasma triglycerides (mmol/L) 19 1.54 ± 0.60 114 2.18 ± 2.68 NS (0.059)
Systolic BP (mmHg) 20 136 ± 21 118 123 ± 16 0.0028
Diastolic BP (mmHg) 20 74 ± 10 118 75 ± 9 NS (0.81)
Hypertensive (%) 20 70.0 118 61.9 NS (0.49)
CRP (mg/L) 19 6.86 ± 12.0 114 4.97 ± 5.87 NS (0.99)
ABI, left 20 0.96 ± 0.12 118 1.09 ± 0.08 <0.0001
ABI, right 20 0.93 ± 0.06 118 1.10 ± 0.08 <0.0001
Intermittent claudication (%) 20 15.0 118 4.2 NS (0.091)
Data are means ± s.d., unless otherwise indicated.
PAD, peripheral arterial disease: ABI <0.95; Hypertension: systolic BP ≥ 130 and/or diastolic BP ≥ 80 and/or antihypertensive treatment.
Abbreviations: BMI, body mass index; HbA1c, glycosylated hemoglobin; BP, blood pressure; CRP, C-reactive protein; ABI, ankle-brachial index; NS, 
not significant.Cardiovascular Diabetology 2005, 4:17 http://www.cardiab.com/content/4/1/17
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mittent claudication (6.12% males vs 62% females, P =
NS [1.00]). Clinical attributes of the subjects, according to
the presence or absence of PAD, are shown in Table 1. Sig-
nificant differences between those with and without PAD
were noted for total cholesterol concentrations and systo-
lic blood pressure, with PAD-affected individuals having,
on average, lower total cholesterol (P = 0.036) and higher
systolic blood pressure (P = 0.0028). There were also
fewer affected individuals taking antidiabetic drugs (P =
0.045).
The overall allele frequencies for the 677C and 677T alle-
les were 0.89 and 0.11, respectively. All 677T carriers were
heterozygotes (677C/T); no 677T/T homozygotes were
found in the population sample studied. There was no sig-
nificant difference found for the 677C>T genotype fre-
quency between sex, with 16.3% of males and 24.7% of
females, respectively, being carriers of the 677T allele (P =
NS [0.25]). There was no significant deviation of the gen-
otype frequencies, overall or according to sex, from those
predicted by Hardy-Weinberg law.
Characteristics of subjects according to the presence or
absence of the 677T allele are presented in Table 2. The
thirty 677T carriers had significantly elevated BMI (32.6 ±
5.5 vs 29.7 ± 4.7 kg/m2, P = 0.0050), and higher systolic
blood pressure (132 ± 22 vs 123 ± 16 mmHg, P = 0.021),
in comparison to 677C/C homozygotes. There was no dif-
ference between 677T carriers and noncarriers regarding
age, waist circumference, % current smoker, duration of
diabetes, % hypertensive, diastolic blood pressure, mean
ABI, and plasma concentrations of fasting blood glucose,
HbA1c, total cholesterol, high-density lipoprotein choles-
terol, low-density lipoprotein cholesterol, triglycerides,
and C-reactive protein.
Association of 677C>T SNP with peripheral arterial 
disease
Significantly more individuals carrying the 677T allele
had PAD, as diagnosed by ABI (26.7% vs 11.1%, P =
0.042); particularly when measured on the right side
(23.3% vs 8.33%, P = 0.047) (Table 3). However, no sig-
nificant difference between carriers and non-carriers was
noted for symptomatic intermittent claudication as deter-
mined by the Rose questionnaire [6.67% vs 5.56%, P = NS
(0.68)].
Multivariate logistic regression (Table 4) revealed that
MTHFR 677C>T genotype was still significantly associ-
ated, albeit marginally, with increased risk of PAD [OR
3.54 (1.01, 12.4), P = 0.049], after adjustment for age, sex,
duration of diabetes, hypertension, current smoking hab-
its, and use of insulin or oral treatment for diabetes. None
of these additional co-variables was significantly associ-
ated with PAD.
Discussion
In Canadian Oji-Cree subjects with type 2 diabetes, we
found that: 1) MTHFR 677T carriers had an increased risk
of PAD [OR 3.54 (1.01, 12.4), P = 0.049], adjusting for
Table 2: Characteristics of Oji-Cree type 2 diabetic patients according to MTHFR 677C>T genotype (max n = 138)
N 677C/C 677C/T P
N (men/women) 138 108 (41/67) 30 (8/22) NS (0.25)
Age (years) 138 46.4 ± 11.1 45.1 ± 13.5 NS (0.60)
BMI (kg/m2) 137 29.7 ± 4.7 32.6 ± 5.5 0.0050
Waist circumference (cm) 137 103 ± 9 106 ± 11 NS (0.063)
Current smoker (%) 138 50.0 50.0 NS (1.00)
Duration of diabetes (years) 138 8.53 ± 6.35 9.20 ± 7.01 NS (0.62)
Fasting glucose (mmol/L) 130 10.20 ± 3.91 9.28 ± 3.03 NS (0.33)
HbA1c (%) 136 8.36 ± 2.25 8.66 ± 2.18 NS (0.47)
Total cholesterol (mmol/L) 133 4.91 ± 1.07 4.67 ± 0.82 NS (0.27)
HDL-C (mmol/L) 133 1.21 ± 0.29 1.21 ± 0.29 NS (0.91)
LDL-C (mmol/L) 130 2.75 ± 0.71 2.70 ± 0.67 NS (0.78)
Plasma triglycerides (mmol/L) 133 2.20 ± 2.78 1.66 ± 0.60 NS (0.15)
Systolic BP (mmHg) 138 123 ± 16 132 ± 22 0.021
Diastolic BP (mmHg) 138 73.9 ± 8.9 77.4 ± 9.4 NS (0.077)
Hypertensive (%) 138 62.0 66.7 NS (0.64)
CRP (mg/L) 133 4.91 ± 6.65 6.53 ± 8.37 NS (0.19)
ABI, left 138 1.08 ± 0.09 1.05 ± 0.12 NS (0.26)
ABI, right 138 1.08 ± 0.09 1.07 ± 0.13 NS (0.73)
Data are means ± s.d., unless otherwise indicated.
Hypertension: systolic BP ≥ 130 and/or diastolic BP ≥ 80 and/or antihypertensive treatment
Abbreviations: BMI, body mass index; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol; BP, blood pressure; CRP, C-reactive protein; ABI, ankle-brachial index; NS, not significant.Cardiovascular Diabetology 2005, 4:17 http://www.cardiab.com/content/4/1/17
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age, sex, duration of diabetes, hypertension, current
smoking habits, and diabetes treatment; and 2) there was
no significant association between MTHFR genotype and
intermittent claudication, a much more advanced stage of
PAD.
Our finding of a significant association between MTHFR
genotype and PAD for subjects with type 2 diabetes is
novel, to our knowledge. Only one other study to date has
examined the relationship between PAD and MTHFR gen-
otype in subjects with type 2 diabetes. In 135 patients
with PAD and 219 controls, Ciccarone et al. found that
though elevated homocysteine levels associated with the
severity of PAD, as assessed by colour-duplex ultrasound,
there was no significant association between MTHFR gen-
otype and PAD [9]. Our observed association is of border-
line statistical significance, yet given that under
multivariate analysis MTHFR genotype was the most sig-
nificant risk factor in comparison to other traditional risk
factors, including smoking, hypertension, and duration of
diabetes, investigation into its potential importance is
warranted.
Though not significant, a 3-fold increased risk of PAD was
observed for subjects who were current smokers. This
finding stresses the importance of smoking cessation pro-
grammes in aboriginal communities, especially given the
high prevalence of smoking in this population (~50% cur-
rent smokers for both males and females). Taking prevent-
ative measures now is also critical considering the
relatively young age of the population. Though the preva-
lence of PAD was ~14%, and the prevalence of intermit-
tent claudication was only ~6%, the mean age of the study
participants was under 50, younger than the majority of
studies involving PAD [9,10,13]. A full expression of dis-
ease phenotypes associated with diabetes for the Oji-Cree
is yet to be seen.
A limitation of our study was the small sample size. With
less than 200 subjects included in each analysis, the power
to detect significant associations was low. Most notably,
the observation of no significant association for any of the
well-known risk factors in the logistic regression analysis
for PAD was likely due to the small sample size. In spite
of the small sample size, the observation of an OR of
greater than 3.5 for the MTHFR genotype and PAD sug-
gests an association of notably strong magnitude which
would be of interest to confirm in future studies.
Our results are also limited by the absence of both dietary
information and plasma folate and homocysteine concen-
trations for our study subjects. Previous studies have
found the prevalence of inadequate dietary folate intake
in the Oji-Cree to be 37%, which is more than twice the
average for the general Canadian population, and may
contribute to compromised MTHFR enzyme activity [34].
Table 3: PAD and intermittent claudication according to MTHFR 677C>T genotype
677C/C n = 108 677C/T n = 30 OR (95% CI) P*
PAD, left or right (n, %) 12 (11.1%) 8 (26.7%) 2.91 (1.06, 7.97) 0.042
PAD, left (n, %) 7 (6.48%) 4 (13.3%) 2.22 (0.60, 8.16) NS (0.25)
PAD, right (n, %) 9 (8.33%) 7 (23.3%) 3.35 (1.13, 9.93) 0.047
Intermittent claudication 
(n, %)
6 (5.56%) 2 (6.67%) 1.20 (0.26, 5.64) NS (0.68)
* Fisher's exact test
Abbreviations: OR, odds ratio; PAD, peripheral arterial disease; NS, not significant.
Table 4: Multivariate associations of risk factors with PAD
Dependent variable Independent variable Unit OR (95% CI) P
PAD, left or right MTHFR 677C>T 677C/T 3.54 (1.01, 12.4) 0.049
oral treatment for diabetes + 0.31 (0.082, 1.20) NS (0.091)
current smoker + 3.04 (0.82, 11.2) NS (0.095)
hypertension + 2.58 (0.58, 11.6) NS (0.22)
age 10 yr 1.36 (0.80, 2.29) NS (0.26)
duration of diabetes 5 yr 0.79 (0.45, 1.38) NS (0.41)
insulin administration + 0.96 (0.18, 5.08) NS (0.97)
sex male 1.00 (0.30, 3.34) NS (0.99)
Hypertension: systolic blood pressure ≥ 130 and/or diastolic blood pressure ≥ 80 and/or antihypertensive treatment.
Abbreviations: OR, odds ratio; PAD, peripheral arterial disease; MTHFR, methylenetetrahydrofolate reductase; NS, not significant.Cardiovascular Diabetology 2005, 4:17 http://www.cardiab.com/content/4/1/17
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These studies, however, took place in an era prior to the
supplementation of the food source with folate, and thus
may be an overestimation of the present situation. Further
detailed clinical measurements would have helped to pro-
vide insight on the relationships between MTHFR geno-
type, plasma homocysteine concentration, and PAD.
Other studies, however, have found significant associa-
tions for homocysteine levels with increased atherosclero-
sis, yet no significant association for MTHFR  genotype
[9,35], raising the question of possible alternative causes
for hyperhomocysteinemia and questioning the real
importance of the MTHFR  genotype. Nonetheless, our
data are consistent with the concept that MTHFR geno-
type may have a mechanistic role in the development and
progression of atherosclerosis in the lower extremities.
Conclusion
In conclusion, we have observed that the presence of the
MTHFR 677T allele was significantly associated with an
~3.5-fold increased risk for PAD, as assessed by ABI, in
subjects with type 2 diabetes. The significance of the rela-
tionship between the MTHFR SNP and ABI was greater
than that of any other common risk factor, including age,
sex, duration of diabetes, hypertension, current smoking
habits, or diabetes treatment. Since this variant is com-
mon, it could represent an important genetic determinant
of PAD risk in the general population.
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